X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (147466) 147466
Newspaper Article (1535) 1535
Newsletter (804) 804
Book Chapter (455) 455
Magazine Article (38) 38
Dissertation (26) 26
Transcript (24) 24
Book / eBook (17) 17
Reference (16) 16
Book Review (11) 11
Conference Proceeding (9) 9
Publication (7) 7
Government Document (5) 5
Web Resource (4) 4
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (80234) 80234
humans (74528) 74528
male (40041) 40041
proteins (39335) 39335
mice (39149) 39149
kinases (28250) 28250
female (27772) 27772
apoptosis (27768) 27768
oncology (25507) 25507
rats (23878) 23878
cancer (22749) 22749
cell biology (22670) 22670
signal transduction (21833) 21833
expression (21541) 21541
research (20284) 20284
phosphorylation (19946) 19946
gene expression (19762) 19762
activation (17800) 17800
biochemistry & molecular biology (17726) 17726
rodents (17635) 17635
neurosciences (17445) 17445
inflammation (16625) 16625
analysis (15055) 15055
research article (14511) 14511
cell line, tumor (14149) 14149
pharmacology & pharmacy (14090) 14090
multidisciplinary sciences (13912) 13912
health aspects (13770) 13770
medicine (13745) 13745
physiological aspects (12929) 12929
oxidative stress (12807) 12807
signal transduction - drug effects (12416) 12416
care and treatment (11687) 11687
disease models, animal (11577) 11577
inhibition (11165) 11165
cells, cultured (11164) 11164
tumors (11142) 11142
mice, inbred c57bl (10814) 10814
physiology (10694) 10694
apoptosis - drug effects (10589) 10589
science (10502) 10502
rats, sprague-dawley (10371) 10371
genetic aspects (10124) 10124
immunology (9902) 9902
middle aged (9895) 9895
cells (9876) 9876
biology (9875) 9875
medicine, research & experimental (9828) 9828
mutation (9693) 9693
cytokines (9539) 9539
studies (8771) 8771
metabolism (8706) 8706
gene-expression (8550) 8550
chemotherapy (8545) 8545
adult (8414) 8414
dose-response relationship, drug (7968) 7968
aged (7917) 7917
in-vitro (7746) 7746
cell cycle (7594) 7594
brain (7557) 7557
review (7546) 7546
protein (7499) 7499
cell proliferation - drug effects (7403) 7403
cell proliferation (7346) 7346
endocrinology & metabolism (7275) 7275
in-vivo (7200) 7200
biochemistry (7117) 7117
enzymes (7008) 7008
cell line (6960) 6960
metastasis (6922) 6922
cancer therapies (6889) 6889
nf-kappa-b (6789) 6789
growth (6511) 6511
medicine & public health (6477) 6477
development and progression (6465) 6465
medical research (6417) 6417
diabetes (6234) 6234
neurology (6231) 6231
neurons (6210) 6210
genes (6196) 6196
antineoplastic agents - pharmacology (6167) 6167
biomedicine (6087) 6087
immunohistochemistry (6011) 6011
blotting, western (5983) 5983
angiogenesis (5964) 5964
disease (5889) 5889
stem cells (5847) 5847
drug therapy (5810) 5810
mice, knockout (5805) 5805
time factors (5785) 5785
pharmacology (5762) 5762
animal models (5728) 5728
signaling (5718) 5718
antineoplastic agents - therapeutic use (5669) 5669
breast cancer (5651) 5651
rats, wistar (5651) 5651
protein kinases (5629) 5629
protein kinase inhibitors - pharmacology (5614) 5614
treatment outcome (5532) 5532
hematology (5524) 5524
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (150026) 150026
Japanese (366) 366
Chinese (159) 159
German (114) 114
French (90) 90
Spanish (29) 29
Russian (25) 25
Portuguese (15) 15
Hungarian (11) 11
Korean (9) 9
Polish (9) 9
Czech (6) 6
Danish (6) 6
Dutch (6) 6
Norwegian (5) 5
Italian (4) 4
Arabic (2) 2
Swedish (2) 2
Turkish (2) 2
Ukrainian (2) 2
Hebrew (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal Article
Drug design, development and therapy, ISSN 1177-8881, 2015, Volume 9, pp. 4479 - 4499
... (LY2157299 monohydrate) is an oral small molecule inhibitor of the TGF-beta receptor I kinase that specifically downregulates the phosphorylation of SMAD2, abrogating activation of the canonical pathway... 
LY2157299 | Clinical trials | TGF-β | TGF-βRI kinase inhibitor | ALK5 | Galunisertib | Cancer | CHEMISTRY, MEDICINAL | RECEPTOR-TYPE-II | MESENCHYMAL TRANSITION | BREAST-CANCER | TGF-beta | HEPATOCELLULAR-CARCINOMA | TGF-beta RI kinase inhibitor | PLASMA-LEVELS | THERAPEUTIC TARGET | REGULATORY T-CELLS | PHARMACOLOGY & PHARMACY | cancer | clinical trials | TUMOR-GROWTH | galunisertib | I KINASE INHIBITOR | Phosphorylation | Pyrazoles - therapeutic use | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Protein Kinase Inhibitors - chemistry | Pyrazoles - chemistry | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Antineoplastic Agents - pharmacokinetics | Molecular Structure | Heart Diseases - chemically induced | Pyrazoles - pharmacokinetics | Protein-Serine-Threonine Kinases - metabolism | Pyrazoles - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Drug Administration Schedule | Administration, Oral | Quinolines - chemistry | Smad2 Protein - metabolism | Neoplasms - enzymology | Treatment Outcome | Antineoplastic Agents - chemistry | Drug Discovery | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Receptors, Transforming Growth Factor beta - antagonists & inhibitors | Receptors, Transforming Growth Factor beta - metabolism | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinolines - therapeutic use | Neoplasms - pathology | Quinolines - adverse effects | Antimitotic agents | Cellular signal transduction | Transforming growth factors | Antineoplastic agents | Health aspects | Testing | Animal models | Transcription factors | Laboratories | Toxicity | Transforming growth factor-b | Oligonucleotides | Glioblastoma | Hepatocellular carcinoma | Metastasis | Vaccines | Kinases | Drug resistance | Dosage | Cancer therapies | Anticancer properties | Metastases | Proteins | Angiogenesis | Signal transduction | Pancreatic carcinoma | Smad2 protein | Fibroblasts | Physiology | Tumorigenesis | Colon | Growth factors | Cytokines | Melanoma | Antisense oligonucleotides | Immunosurveillance | Pharmacology | Breast cancer | Lung carcinoma | Patients | Biological activity | Signaling | Inhibitors | Pancreatic cancer | Monoclonal antibodies | Ligands | Antitumor activity | Prostate cancer | Tumors
Journal Article
British journal of cancer, ISSN 0007-0920, 02/2019, Volume 120, Issue 3, pp. 286 - 293
BACKGROUND: This phase I, open-label, dose-escalation study evaluated the safety, pharmacokinetics and pharmacodynamics of combination therapy with the HDM2 inhibitor SAR405838 and the MEK1/2 inhibitor... 
Thrombocytopenia/chemically induced | Humans | Middle Aged | Proto-Oncogene Proteins p21(ras)/genetics | Proto-Oncogene Proteins B-raf/genetics | MAP Kinase Kinase Kinases/antagonists & inhibitors | Male | Gene Expression Regulation, Neoplastic/drug effects | Tumor Suppressor Protein p53/genetics | Niacinamide/administration & dosage | Spiro Compounds/administration & dosage | Proto-Oncogene Proteins c-mdm2/antagonists & inhibitors | Dose-Response Relationship, Drug | Indoles/administration & dosage | Protein Kinase Inhibitors/administration & dosage | Maximum Tolerated Dose | Neoplasms/classification | Adult | Female | Aged | Antineoplastic Combined Chemotherapy Protocols/administration & dosage | ACTIVATION | P53 PATHWAY | ONCOLOGY | RG7112 | Niacinamide - analogs & derivatives | Proto-Oncogene Proteins c-mdm2 - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Proto-Oncogene Proteins p21(ras) - genetics | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Spiro Compounds - administration & dosage | Protein Kinase Inhibitors - adverse effects | Spiro Compounds - adverse effects | Indoles - administration & dosage | Tumor Suppressor Protein p53 - genetics | Neoplasms - genetics | Niacinamide - pharmacokinetics | Gene Expression Regulation, Neoplastic - drug effects | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-mdm2 - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase Kinases - genetics | Niacinamide - adverse effects | Neoplasms - classification | Thrombocytopenia - chemically induced | Thrombocytopenia - pathology | Spiro Compounds - pharmacokinetics | Neoplasms - drug therapy | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Indoles - pharmacokinetics | Neoplasms - pathology | Index Medicus | Targeted therapies | Outcomes research
Journal Article
Cancer Research, ISSN 0008-5472, 10/2004, Volume 64, Issue 19, pp. 7099 - 7109
Journal Article
American journal of physiology. Cell physiology, ISSN 0363-6143, 03/2016, Volume 310, Issue 5, pp. C373 - C380
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 773 - 781
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
... – 5 Crizotinib is an oral small-molecule tyrosine kinase inhibitor of ALK, MET, and ROS1 kinases... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 6, p. e100880
.... GSK2110183 and GSK2141795 are orally bioavailable, potent inhibitors of the AKT kinases that have progressed to human clinical studies... 
BREAST-CANCER | APOPTOSIS | ACTIVATING MUTATION | PHOSPHORYLATION | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | PLECKSTRIN HOMOLOGY DOMAIN | RICTOR | INDUCTION | EGFR | Ribosomal Protein S6 Kinases - metabolism | Pyrazoles - chemical synthesis | Antineoplastic Agents - chemical synthesis | Humans | Gene Expression Regulation, Neoplastic | Phosphatidylinositol 3-Kinases - metabolism | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - genetics | Pancreatic Neoplasms - drug therapy | PTEN Phosphohydrolase - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Drug Evaluation, Preclinical | MAP Kinase Kinase Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-akt - metabolism | Pyrazoles - pharmacology | PTEN Phosphohydrolase - genetics | Protein Kinase Inhibitors - chemical synthesis | Signal Transduction | Administration, Oral | MAP Kinase Kinase Kinases - genetics | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - enzymology | PTEN Phosphohydrolase - metabolism | Pancreatic Neoplasms - genetics | MAP Kinase Kinase Kinases - metabolism | Mice, SCID | Drug Synergism | Phosphatidylinositol 3-Kinases - genetics | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Cell Line, Tumor | Diamines - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Blood Glucose - metabolism | Diamines - chemical synthesis | Ribosomal Protein S6 Kinases - antagonists & inhibitors | Ribosomal Protein S6 Kinases - genetics | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Cellular signal transduction | Glucose | Phosphotransferases | Dextrose | Tumors | Biotechnology | Phosphorylation | Animal models | Leukemia | Homeostasis | Oncology | AKT protein | Kinases | K-Ras protein | Anticancer properties | Feedback | Polyethylene glycol | Inhibition | Enzymes | Tumor cells | MAP kinase | Breast cancer | Bioavailability | Substrates | 1-Phosphatidylinositol 3-kinase | Studies | Signaling | Inhibitors | Pancreatic cancer | Mutation | Laboratory animals | ATP | PTEN protein | Cancer | Apoptosis
Journal Article